Gerresheimer Forced into Major Asset Sale Amid Financial Crisis

The pharmaceutical packaging group Gerresheimer finds itself in a precarious financial position, despite projecting billions in revenue for the current year. Operational missteps have pushed the company into technical default on its credit agreements, primarily due to the absence of an audited financial statement for 2025. In a drastic move to prevent lenders from calling in their loans, management has initiated the sale of its most profitable division.

Regulatory Scrutiny and Balance Sheet Cleanup

The root of the current turmoil lies in flawed accounting practices from previous years. Internal probes have confirmed breaches of IFRS standards related to revenue recognition and inventory reporting. Last month, Germany’s financial regulator, BaFin, expanded its investigation into the matter. Authorities are now examining 65.5 million euros in lease liabilities and 29.4 million euros in capitalized development costs from the 2024 fiscal year.

Cleaning up the balance sheet will come at a significant cost. For its pending 2025 consolidated statement, Gerresheimer is preparing to book impairment charges between 220 and 240 million euros. These write-downs will primarily target technology projects at Sensile Medical AG and the fixed assets of its Chicago plant. This toxic combination of events has triggered a massive sell-off in the company’s shares. Since peaking in September 2023, the stock has plummeted approximately 88 percent to its current level of 19.25 euros.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Strategic Retreat from the U.S. Market

Concurrently, Gerresheimer is accelerating its operational withdrawal from the United States. Its glass manufacturing facility in Chicago Heights is slated for permanent closure by the end of 2026. Production from this site will be relocated to existing plants in Italy and India.

The centerpiece of the company’s survival strategy is the divestment of its U.S. subsidiary, Centor Inc. Management has engaged investment bank Morgan Stanley to finalize the transaction before the close of this year. Specializing in packaging for prescription drugs, the Centor unit carried a book value of 292 million euros at the end of 2024. Proceeds from this fire sale are deemed essential to stabilize the parent company’s strained capital structure.

Leadership is attempting to countersteer through a strict cost-cutting initiative dubbed the “gto” transformation program. However, the definitive verdict on the firm’s financial future will come in June 2026. By that deadline, Gerresheimer must present its audited financial statements. These documents are a mandatory prerequisite for the final extension of its bank credit facilities and for confirming its revenue forecast of up to 2.4 billion euros.